Klippel-Trénaunay Syndrome

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Klippel-Trénaunay Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • KTS

Disorder Subdivisions

  • None

General Discussion


Klippel-Trénaunay syndrome (KTS) is a rare disorder that is present at birth (congenital) and is characterized by a triad of cutaneous capillary malformation ("port-wine stain"), lymphatic anomalies, and abnormal veins in association with variable overgrowth of soft tissue and bone. KTS occurs most frequently in the lower limb and less commonly in the upper extremity and trunk. KTS equally affects males and females.


The eponym KTS has generated controversy in the medical literature since the first report of the condition in the early 20th century. The French physicians, Klippel and Trénaunay, described patients with capillary stains (improperly called "hemangiomas" at that time), venous varicosities, and overgrowth. At about the same time, the English dermatologist Parkes Weber reported the combination of "hemangiomas" and overgrowth of a limb. For many years, the names of all three physicians were linked as a confusing (and incorrect) term "Klippel-Weber-Trénaunay syndrome," which still is (unfortunately) used to this day.

Since the latter 20th century, it is well-recognized that Parkes Weber and Klippel-Trénaunay syndromes are entirely different. Parkes Weber syndrome consists of fast-flow, multiple microscopic arteriovenous connections with variable capillary staining of an enlarged limb (usually the lower extremity). By genetic testing, many of these patients have a dominant, germline mutation in the gene RASA1.

In contrast, KTS is a slow-flow combined vascular disorder involving abnormal capillaries (C), lymphatics (L) and veins (V). Therefore, many investigators use the abbreviation CLVM, rather than KTS, and restrict the designation for patients who have all three vascular anomalies. Other authors apply the KTS term more broadly and include patients with only capillary stain (CM) or only capillary and venous anomalies (CVM) in the limb in the absence of lymphatic abnormalities.

Once the genetic cause for KTS is discovered, it will be possible to more precisely designate patients with these various combinations of vascular anomalies.


Capillary Malformation (CM)

At birth, KTS presents with scattered, geographic capillary stains. With age, the surface of the CM becomes studded with tiny lymphatic vesicles that often turn black due to intralesional bleeding.

Lymphatic Malformation (LM)

LM presents as localized or generalized overgrowth caused by micro- and macrocystic anomalies, sometimes in association with lymphedema. Often there is lymphatic swelling and fatty deposition on the contralateral foot. The lymphatic anomalies can also occur in the pelvis, bladder and lower gastrointestinal tract. Lymphatic cysts in the spleen are also common. LM is documented by ultrasonography and/or MRI. Lymphography shows that lymphedema is the result of diminished number or absence of lymphatic channels.

Episodic infections (cellulitis) are common and probably related to poor lymphatic drainage in the limb.

Venous Malformation (VM)

Venous abnormalities are always present but variable and involve the entire affected extremity. Typically there are anomalous embryonic veins called the "marginal system." Dilatation of superficial veins may not be apparent in infancy, but becomes more prominent with age. LM and VM can also involve the pelvic or abdominal organs resulting in bleeding from the rectum, vagina or urinary bladder. Abnormal fatty deposits accompany the venous and lymphatic anomalies.

Stagnant blood in the abnormal veins may clot and trigger a bleeding disorder called "disseminated intravascular coagulopathy."


Enlargement of the limb can be minimal to grotesque. Overgrowth in length is typical; however, in some patients the affected limb is shorter than normal. Frequently there is enlargement of the opposite foot.


The cause of KTS is unknown. The presumption is that it begins as a new gene mutation in primitive cells that form a limb that were destined to form blood and lymphatic vessels, fat, and bones. Researchers are actively trying to discover this mutation.

Affected Populations

Klippel-Trénaunay Syndrome is a rare disorder affecting males and females in equal numbers. The disorder occurs worldwide.

Standard Therapies


KTS is diagnosed based on physical signs and symptoms. Computed axial tomography (CAT) and magnetic resonance imaging (MRI) scans, and color doppler studies may be useful in determining the scope of the syndrome and how best to manage it.


Recommended management for the following malformations associated with KTS is as follows:

Capillary Malformation

The vesicles in the CM can be improved by laser therapy, sclerotherapy or sometimes

resection and closure or replacement with a split-thickness skin graft.

Lymphatic Malformation

Macrocystic LM can be deflated by sclerotherapy (injection of irritating solutions), whereas, microcystic LM requires resection.

Venous Malformation

Blood stagnates in large dilated veins, and thus there is a risk for initiating a clotting disorder or thrombosis and pulmonary embolism. Anticoagulation with heparin is often necessary prior to radiologic or surgical intervention. Large venous channels can be obliterated by sclerotherapy or endovascular laser. Chronic bleeding from the colon may require surgical resection. Bleeding lesions in the bladder can be controlled by laser done through a cystoscope. An elastic compressive stocking is often useful to minimize discomfort and swelling due to venous distension.


Enlarged toes may require amputation to narrow the foot and permit footwear. Discrepancy in leg length can be corrected by inserting a lift in the shoe on the normal foot to prevent compensatory curvature of the spine (scoliosis). Surgical closure of the growth plate at the knee (epiphysiodesis) is often needed to equalize leg length.

Staged contour resection is possible to diminish girth of the limb. These procedures are less effective if the abnormal fat and vasculature extends beneath the deep fascia of the leg into the muscle layer.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:


Contact for additional information about Klippel-Trénaunay syndrome:

John B. Mulliken, MD,

Co-Director, Vascular Anomalies Center

Director, Craniofacial Centre

Boston Children's Hospital

300 Longwood Avenue

Boston, MA 02115




Oduber CEU, van der Horst CMAM, Hennekam RCM. Klippel-Trénaunay syndrome: diagnostic criteria and hypothesis on etiology. Ann Plast Surg. 2008;60(2):217-23.

Delis KT, Gloviczki P, Wennberg T, et al. Hemodynamic impairment, venous segmental disease (VSDS) and clinical severity (VCSS) scoring in limbs with Klippel-Trénaunay syndrome. J. Vasc.Surg. 2007;45:56-567.

Husmann DA, Rathburn SR, Driscoll DJ. Klippel-Trénaunay syndrome: incidence and treatment of genitourinary sequelae. J Urol. 2007;177(4):1244-9.

Cohen MM Jr. Klippel-Trénaunay syndrome. Am J Med Genet. 2000 Jul;93(3):171-5.

Jacob A, Driscoll D, Shaugnessy W, et al. Klippel-Trénaunay syndrome: Its spectrum and management . Mayo Clinic Proc. 1998;73:28-36

Happle R. Klipple-Trénaunay syndrome: Is it a paradominant trait? Br J. Dermatol. 1993;128:465-66.


Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Klippel-Trénaunay-Weber syndrome. Entry No: 149000. Last Edited July 3, 2012. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed July 12, 2012.


March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763

Internet: http://www.marchofdimes.com

Klippel-Trenaunay Support Group

1471 Greystone Lane

Milford, OH 45150

Tel: (513)722-7724

Fax: (952)925-2596

Email: ktnewmembers@gmail.com

Internet: http://www.k-t.org

Lymphovenous Canada

8 Silver Ave


Ontario, M6R 1X8


Tel: 4165332428

Email: info@lymphovenous-canada.ca

Internet: http://www.lymphovenous-canada.ca

Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org

National Organization of Vascular Anomalies

PO Box 38216

Greensboro, NC 27438-8216

Email: admin@mail.novanews.org

Internet: http://www.novanews.org

Hemihypertrophy Support

4581 Magnolia Dr.

Suffolk, VA 23435

Tel: (757)615-3686

Email: hemihypertrophy@yahoogroups.com

Internet: http://www.hemisupport.com

Venous Disease Coalition

1075 S. Yukon Street, Suite 320

Suite 320

Lakewood, CO 80226

Tel: (303)989-0500

Fax: (303)989-0200

Tel: (888)833-4463

Email: info@venousdiseasecoalition.org

Internet: http://www.venousdiseasecoalition.org

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.